| Identification | Back Directory | [Name]
TIANEPTINE | [CAS]
72797-41-2 | [Synonyms]
TPI-1062
Tianeptin
JNJ-39823277
Einecs 276-851-9
7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoic acid
7-[(3-Chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid
(±)-7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide
(1)-7-((3-Chloro-6,11-dihydro-6-methyldibenzo(C,F)(1,2)thiazepin-11-yl)amino)heptanoic acid S,S-dioxide | [EINECS(EC#)]
276-851-9 | [Molecular Formula]
C21H25ClN2O4S | [MDL Number]
MFCD00865376 | [MOL File]
72797-41-2.mol | [Molecular Weight]
436.95 |
| Chemical Properties | Back Directory | [Melting point ]
129-131?C | [Boiling point ]
609.2±65.0 °C(Predicted) | [density ]
1.38±0.1 g/cm3(Predicted) | [vapor pressure ]
0.001Pa at 25℃ | [storage temp. ]
Refrigerator, Under Inert Atmosphere | [form ]
solid
| [pka]
4.75±0.10(Predicted) | [InChI]
InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26) | [InChIKey]
JICJBGPOMZQUBB-UHFFFAOYSA-N | [SMILES]
C(O)(=O)CCCCCCNC1C2=CC=C(Cl)C=C2S(=O)(=O)N(C)C2=CC=CC=C21 | [LogP]
2.162 at 25℃ and pH6 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Tricyclic compound with psychostimulant, anti-ulcer and anti-emetic properties. Antidepressant. | [Definition]
ChEBI:Tianeptine is a racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). It has a role as a mu-opioid receptor agonist, a second generation antipsychotic and an anxiolytic drug. It contains a (R)-tianeptine and a (S)-tianeptine. | [Brand name]
Stablon, Tatinol, and Coaxil among others | [Mechanism of action]
Current research suggests that tianeptine produces its antidepressant effects through the modulation of glutamate receptor activity (for example, AMPA receptors and NMDA receptors) and affect the release of brain-derived neurotrophic factor (BDNF), which impacts neural plasticity. |
|
|